Stem Cell Transplantation in Crohn's Disease
NCT04224558
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Unfortunately, some patients with Crohn's disease (CD) fail to respond to the best clinical treatments and some only experience temporary benefit. For severe Crohn's disease, there is an experimental treatment called "high dose immunoablation" followed by autologous hematopoietic stem cell transplantation (HSCT). This study removes over active lymphocytes (immunoablation) and replaces them using blood stem cells that have been taken from the patient's own body. The aim of the study is to reset or reprogram the patient's immune system to its state prior to diagnosis.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Crohn Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 13 to 28 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Cedars-Sinai Medical Center
- Last updated on ClinicalTrials.gov
- February 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Cedars-Sinai Medical Center · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.